Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy

INTRODUCTION: Immunotherapy is the new standard of care in advanced non-small cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferdinandus, Justin, Metzenmacher, Martin, Kessler, Lukas, Umutlu, Lale, Aigner, Clemens, Kambartel, Karl-Otto, Grünwald, Viktor, Eberhardt, Wilfried Ernst Erich, Fendler, Wolfgang Peter, Herrmann, Ken, Faehling, Martin, Christoph, Daniel Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016096/
https://www.ncbi.nlm.nih.gov/pubmed/33789880
http://dx.doi.org/10.1136/jitc-2020-002262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016096/
https://www.ncbi.nlm.nih.gov/pubmed/33789880
http://dx.doi.org/10.1136/jitc-2020-002262

Ejemplares similares